chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Confusional state, Headache, Hypoacusis, Influenza like illness, Reading disorder
Clinical narrative: Disoriented (Agent Observation); Hard to hear (Agent Observation); Vision dropped by 50%  After Second Dose; Can not read Newspaper After Second Dose; Headache After Second Dose; Flu Like Symptoms After Second Dose; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose), VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose), READING DISORDER (Can not read Newspaper After Second Dose), CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)) in a 96-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose) and HEADACHE (Headache After Second Dose). In March 2021, the patient experienced VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose) and READING DISORDER (Can not read Newspaper After Second Dose). On 09-Jun-2021, the patient experienced CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)). On 23-Feb-2021, HEADACHE (Headache After Second Dose) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose), VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose), READING DISORDER (Can not read Newspaper After Second Dose), CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)) outcome was unknown.            The patient reported he visited an eye doctor on 26-MAY-2021 and was told his vision problems might be due to his age. The eye doctor prescribed glasses but the patient had not yet purchased them at the time of the report.  No concomitants medication were provided. No lab data has been provided by the reporter.
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Visual impairment
Clinical narrative: Disoriented (Agent Observation); Hard to hear (Agent Observation); Vision dropped by 50%  After Second Dose; Can not read Newspaper After Second Dose; Headache After Second Dose; Flu Like Symptoms After Second Dose; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose), VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose), READING DISORDER (Can not read Newspaper After Second Dose), CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)) in a 96-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose) and HEADACHE (Headache After Second Dose). In March 2021, the patient experienced VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose) and READING DISORDER (Can not read Newspaper After Second Dose). On 09-Jun-2021, the patient experienced CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)). On 23-Feb-2021, HEADACHE (Headache After Second Dose) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu Like Symptoms After Second Dose), VISUAL IMPAIRMENT (Vision dropped by 50%  After Second Dose), READING DISORDER (Can not read Newspaper After Second Dose), CONFUSIONAL STATE (Disoriented (Agent Observation)) and HYPOACUSIS (Hard to hear (Agent Observation)) outcome was unknown.            The patient reported he visited an eye doctor on 26-MAY-2021 and was told his vision problems might be due to his age. The eye doctor prescribed glasses but the patient had not yet purchased them at the time of the report.  No concomitants medication were provided. No lab data has been provided by the reporter.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure measurement, Product dose omission issue
Clinical narrative: Second shot more than 42 days/Patient never had second shot; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second shot more than 42 days/Patient never had second shot) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Prostate cancer, AFib and Coagulation defects, other and unspecified.    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second shot more than 42 days/Patient never had second shot). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second shot more than 42 days/Patient never had second shot) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: high (High) High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment details were provided.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Intentional product use issue
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of intentional product use issue (patient had to reschedule her second dose; second dose will be on day 36) and fatigue (very tired for a day or two) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On May 5, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced intentional product use issue (patient had to reschedule her second dose; second dose will be on day 36) and fatigue (very tired for a day or two). At the time of the report, intentional product use issue (patient had to reschedule her second dose; second dose will be on day 36) and fatigue (very tired for a day or two) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No concomitant medication, treatment information or lab data provided.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site haemorrhage
Clinical narrative: Bleeding at the injection site; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE HAEMORRHAGE (Bleeding at the injection site) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE HAEMORRHAGE (Bleeding at the injection site). At the time of the report, VACCINATION SITE HAEMORRHAGE (Bleeding at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided by the reporter.    Reporter did not allow further contact
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Muscle spasms, Muscular weakness
Clinical narrative: Had weakness in legs; legs cramping; increased fatigue; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (Had weakness in legs), MUSCLE SPASMS (legs cramping) and FATIGUE (increased fatigue) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis. Concomitant products included TERIFLUNOMIDE (AUBAGIO) from 03-Feb-2018 to an unknown date for Multiple sclerosis.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2021, the patient experienced FATIGUE (increased fatigue). On an unknown date, the patient experienced MUSCULAR WEAKNESS (Had weakness in legs) and MUSCLE SPASMS (legs cramping). At the time of the report, MUSCULAR WEAKNESS (Had weakness in legs) and MUSCLE SPASMS (legs cramping) had not resolved and FATIGUE (increased fatigue) outcome was unknown.            No treatment medication was reported.  For mRNA-1273 (COVID 19 Vaccine Moderna), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Follow-up contains No new information
Sex: M
Vaccine: COVID19
Symptoms: Electrolyte imbalance, Fatigue, Headache, Nausea, Peripheral swelling
Clinical narrative: Vitamin D deficiency; Electrolytes deficiency; Swollen hands and feet; Head ache; Fatigue; Nauseated; This spontaneous case was reported by a consumer and describes the occurrence of VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache) and FATIGUE (Fatigue) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache), FATIGUE (Fatigue) and NAUSEA (Nauseated). The patient was treated with COLECALCIFEROL (VITAMIN D 3) for Vitamin D deficiency, at an unspecified dose and frequency and GLUCOSE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM CITRATE DIHYDRATE (ORS [GLUCOSE;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE]) for Electrolyte disturbance, at an unspecified dose and frequency. At the time of the report, VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache), FATIGUE (Fatigue) and NAUSEA (Nauseated) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Laboratory data was blood works returned bad.
Sex: M
Vaccine: COVID19
Symptoms: Vitamin D deficiency
Clinical narrative: Vitamin D deficiency; Electrolytes deficiency; Swollen hands and feet; Head ache; Fatigue; Nauseated; This spontaneous case was reported by a consumer and describes the occurrence of VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache) and FATIGUE (Fatigue) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache), FATIGUE (Fatigue) and NAUSEA (Nauseated). The patient was treated with COLECALCIFEROL (VITAMIN D 3) for Vitamin D deficiency, at an unspecified dose and frequency and GLUCOSE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM CITRATE DIHYDRATE (ORS [GLUCOSE;POTASSIUM CHLORIDE;SODIUM CHLORIDE;SODIUM CITRATE DIHYDRATE]) for Electrolyte disturbance, at an unspecified dose and frequency. At the time of the report, VITAMIN D DEFICIENCY (Vitamin D deficiency), ELECTROLYTE IMBALANCE (Electrolytes deficiency), PERIPHERAL SWELLING (Swollen hands and feet), HEADACHE (Head ache), FATIGUE (Fatigue) and NAUSEA (Nauseated) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Laboratory data was blood works returned bad.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (vaccination site pain) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concurrent medical conditions included Back pain (diagnosed 20 years ago). Concomitant products included GABAPENTIN for Back pain.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Feb-2021, the patient experienced VACCINATION SITE PAIN (vaccination site pain). On 10-Feb-2021, VACCINATION SITE PAIN (vaccination site pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication was not provided. No lab data has been provided by the reporter.    This case was linked to MOD-2021-044817 (Patient Link).
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Second dose of the Moderna Covid-19 Vaccine potentially on the 46th day; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second dose of the Moderna Covid-19 Vaccine potentially on the 46th day) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second dose of the Moderna Covid-19 Vaccine potentially on the 46th day). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second dose of the Moderna Covid-19 Vaccine potentially on the 46th day) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitants medication were provided. No treatment medication were provided. No lab data has been provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Induration, Rash, Rash erythematous, Rash pruritic
Clinical narrative: I had a red rash about the size of a tennis ball by about Day 9 or day 10; itched; burned; was somewhat painful; I had a red rash about the size of a tennis ball by about Day 9 or day 10; It was firm; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful) and SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm). At the time of the report, RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: I had a red rash about the size of a tennis ball by about Day 9 or day 10; itched; burned; was somewhat painful; I had a red rash about the size of a tennis ball by about Day 9 or day 10; It was firm; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful) and SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm). At the time of the report, RASH ERYTHEMATOUS (I had a red rash about the size of a tennis ball by about Day 9 or day 10), RASH PRURITIC (itched), BURNING SENSATION (burned), RASH (was somewhat painful), SWELLING (I had a red rash about the size of a tennis ball by about Day 9 or day 10) and INDURATION (It was firm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: may i take my second shot 40 days after the first?; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may i take my second shot 40 days after the first?) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may i take my second shot 40 days after the first?). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (may i take my second shot 40 days after the first?) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient declined for follow up. No concomitant medication were reported. No treatment medications were reported. No lab data has been provided by the reporter.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia
Clinical narrative: arm soreness; fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness) and PYREXIA (fever) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was provided by the reporter.  Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL HCTZ) for Blood pressure management.    On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-May-2021, the patient experienced PAIN IN EXTREMITY (arm soreness) and PYREXIA (fever). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (arm soreness) and PYREXIA (fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to MOD-2021-215288 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Diarrhoea, Dyspepsia
Clinical narrative: a terrible diarrhea and it caused to flare in her digestive issues; a terrible diarrhea and it caused to flare in her digestive issues; Dyspepsia; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 10-Jun-2021 and was forwarded to Moderna on 10-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (a terrible diarrhea and it caused to flare in her digestive issues), CONDITION AGGRAVATED (a terrible diarrhea and it caused to flare in her digestive issues) and DYSPEPSIA (Dyspepsia) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Diverticulosis.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (a terrible diarrhea and it caused to flare in her digestive issues), CONDITION AGGRAVATED (a terrible diarrhea and it caused to flare in her digestive issues) and DYSPEPSIA (Dyspepsia). The patient was treated with LOPERAMIDE HYDROCHLORIDE for Diarrhoea, at a dose of 1 dosage form. At the time of the report, DIARRHOEA (a terrible diarrhea and it caused to flare in her digestive issues), CONDITION AGGRAVATED (a terrible diarrhea and it caused to flare in her digestive issues) and DYSPEPSIA (Dyspepsia) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was reported that the patient started taking teriflunomide Coated tablet 14 mg QD oral on 04-mar-2021.Around the same time of starting the Aubagio, the patient received her Moderna COVID vaccine, so the doctor was not sure which was causing the diarrhea but the Aubagio had been discontinued.
Sex: U
Vaccine: COVID19
Symptoms: Irritable bowel syndrome
Clinical narrative: IBS flare; This spontaneous case was reported by a patient and describes the occurrence of IRRITABLE BOWEL SYNDROME (IBS flare) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IRRITABLE BOWEL SYNDROME (IBS flare). At the time of the report, IRRITABLE BOWEL SYNDROME (IBS flare) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. No  concomitant medication provided by the reporter. no treatment information provided by the reporter
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022B21A and unknown) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.). On 09-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. No treatment medication was provided. No lab data has been provided by the reporter.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia
Clinical narrative: Loss of smell; Loss of taste; This spontaneous case was reported by a dentist and describes the occurrence of ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste). At the time of the report, ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia
Clinical narrative: Loss of smell; Loss of taste; This spontaneous case was reported by a dentist and describes the occurrence of ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste). At the time of the report, ANOSMIA (Loss of smell) and AGEUSIA (Loss of taste) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. No further information is expected.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Nausea, Vaccination site pain, Vaccination site warmth
Clinical narrative: Was tired; At the injection site there was a little burning, and it felt hot; At the injection site there was a little burning, and it felt hot; Patient got a little nauseous; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (At the injection site there was a little burning, and it felt hot), NAUSEA (Patient got a little nauseous), FATIGUE (Was tired) and VACCINATION SITE PAIN (At the injection site there was a little burning, and it felt hot) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M2DA) for COVID-19 vaccination.     No medical history was provided by the reporter.  The patient's past medical history included GERD (GERD described as acid reflux.), Kidney stones, Bladder discomfort (Bladder problems) and Spasms (Back spasms.). Concurrent medical conditions included COPD, Arthritis, Blood pressure and Anxiety. Concomitant products included BACLOFEN for Spasms, SALBUTAMOL SULFATE (PROAIR [SALBUTAMOL SULFATE]), MONTELUKAST SODIUM (SINGULAIR) and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, the patient experienced VACCINATION SITE WARMTH (At the injection site there was a little burning, and it felt hot), NAUSEA (Patient got a little nauseous) and VACCINATION SITE PAIN (At the injection site there was a little burning, and it felt hot). On 26-Feb-2021, the patient experienced FATIGUE (Was tired). On 25-Feb-2021, VACCINATION SITE WARMTH (At the injection site there was a little burning, and it felt hot), NAUSEA (Patient got a little nauseous) and VACCINATION SITE PAIN (At the injection site there was a little burning, and it felt hot) had resolved. At the time of the report, FATIGUE (Was tired) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Blood pressure medicine, acid reflux medicine, anxiety medicine, COPD inhaler were the concomitant medications provided.  No treatment drug details was provided.   This case was linked to MOD-2021-215265 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Couldn't reach appointment for the second dose on the 7May2021; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Couldn't reach appointment for the second dose on the 7May2021) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Couldn't reach appointment for the second dose on the 7May2021). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Couldn't reach appointment for the second dose on the 7May2021) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No Concomitant medications were reported. No Treatment medications were reported.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Malaise
Clinical narrative: not feeling well; not feeling well; lost of appetite; This spontaneous case was reported by a consumer and describes the occurrence of the first episode of MALAISE (not feeling well), the second episode of MALAISE (not feeling well) and DECREASED APPETITE (lost of appetite) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 002A21A) for COVID-19 vaccination.     Concomitant products included CICLOSPORIN (RESTASIS) for Dry eyes, RIVAROXABAN (XARELTO), DILTIAZEM HYDROCHLORIDE (CARTIA XT), FLECAINIDE, ESTRADIOL (ESTRADIOL SANDOZ), LEVOSALBUTAMOL TARTRATE (XOPENEX HFA) and FLUTICASONE PROPIONATE (FLOVENT) for an unknown indication.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Feb-2021, the patient experienced the first episode of MALAISE (not feeling well), the second episode of MALAISE (not feeling well) and DECREASED APPETITE (lost of appetite). The patient was treated with HISTAMINE at a dose of 1 dosage form and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form. In February 2021, last episode of MALAISE (not feeling well) and DECREASED APPETITE (lost of appetite) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-215308 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Hypovitaminosis
Clinical narrative: all her vitamins are gone, Vitamin C, Vitamin D, potassium, and Vitamin A gone; tiredness was bad, described as its being beyond tiredness,could not get out of bed to cook a dinner because of the tiredness symptom; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (tiredness was bad, described as its being beyond tiredness,could not get out of bed to cook a dinner because of the tiredness symptom) and HYPOVITAMINOSIS (all her vitamins are gone, Vitamin C, Vitamin D, potassium, and Vitamin A gone) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019821A) for COVID-19 vaccination.     The patient's past medical history included GERD, Kidney stones, Bladder disorder and Spasms. Concurrent medical conditions included COPD and Arthritis. Concomitant products included BACLOFEN, MONTELUKAST SODIUM (SINGULAIR) and baby aspirin 81 mg for an unknown indication.    On 01-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, the patient experienced FATIGUE (tiredness was bad, described as its being beyond tiredness,could not get out of bed to cook a dinner because of the tiredness symptom). On an unknown date, the patient experienced HYPOVITAMINOSIS (all her vitamins are gone, Vitamin C, Vitamin D, potassium, and Vitamin A gone). At the time of the report, FATIGUE (tiredness was bad, described as its being beyond tiredness,could not get out of bed to cook a dinner because of the tiredness symptom) and HYPOVITAMINOSIS (all her vitamins are gone, Vitamin C, Vitamin D, potassium, and Vitamin A gone) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Other concomitant medications include blood pressure medicine, acid reflux medicine, anxiety medicine, Proair, COPD inhaler. No treatment medication was provided by the reporter. No lab data was provided by the reporter.
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Chills, Erythema, Myalgia, Pruritus
Clinical narrative: Became very red; Itchy; Rashes on my chest; Fever; Chills; My arm starts hurting,Under my shoulders hurts\deltoid pain; Chest hurts,Chest pain is getting worse; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Chest hurts,Chest pain is getting worse), ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 078C21A and 046B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021 at 12:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Jun-2021, the patient experienced CHEST PAIN (Chest hurts,Chest pain is getting worse). On an unknown date, the patient experienced ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever), CHILLS (Chills), RASH (Rashes on my chest) and MYALGIA (My arm starts hurting,Under my shoulders hurts\deltoid pain). The patient was treated with KETOROLAC on 11-Jun-2021 at a dose of 10mg and IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency. On 28-Jun-2021, RASH (Rashes on my chest) had resolved with sequelae. At the time of the report, CHEST PAIN (Chest hurts,Chest pain is getting worse) had resolved with sequelae and ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever), CHILLS (Chills) and MYALGIA (My arm starts hurting,Under my shoulders hurts\deltoid pain) outcome was unknown.            No concomitant medication was reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: Follow-up received on 8-JULY-2021 and added patient details, product dose info updated, added new e vents,added outcome of the events.
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Rash
Clinical narrative: Became very red; Itchy; Rashes on my chest; Fever; Chills; My arm starts hurting,Under my shoulders hurts\deltoid pain; Chest hurts,Chest pain is getting worse; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Chest hurts,Chest pain is getting worse), ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 078C21A and 046B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021 at 12:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Jun-2021, the patient experienced CHEST PAIN (Chest hurts,Chest pain is getting worse). On an unknown date, the patient experienced ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever), CHILLS (Chills), RASH (Rashes on my chest) and MYALGIA (My arm starts hurting,Under my shoulders hurts\deltoid pain). The patient was treated with KETOROLAC on 11-Jun-2021 at a dose of 10mg and IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency. On 28-Jun-2021, RASH (Rashes on my chest) had resolved with sequelae. At the time of the report, CHEST PAIN (Chest hurts,Chest pain is getting worse) had resolved with sequelae and ERYTHEMA (Became very red), PRURITUS (Itchy), PYREXIA (Fever), CHILLS (Chills) and MYALGIA (My arm starts hurting,Under my shoulders hurts\deltoid pain) outcome was unknown.            No concomitant medication was reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: Follow-up received on 8-JULY-2021 and added patient details, product dose info updated, added new e vents,added outcome of the events.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Weight increased
Clinical narrative: Chronic Fatigue Syndrome; Night sweats; Brain fog; Pain; Menstrual cramps; Bloating in stomach area; Spotting; Fatigue; Sleeplessness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Pain), FEELING ABNORMAL (Brain fog), DYSMENORRHOEA (Menstrual cramps), ABDOMINAL DISTENSION (Bloating in stomach area) and INTERMENSTRUAL BLEEDING (Spotting) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044B21A and 038B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included GERD from 05-May-2019 to February 2020 and Menopause (Hormonal adjustments due to Menopause.). Concurrent medical conditions included Migraine.   On 15-Apr-2021 at 3:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-May-2021 at 3:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-May-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INSOMNIA (Sleeplessness). On 28-May-2021, the patient experienced FATIGUE (Fatigue). On 05-Jun-2021, the patient experienced DYSMENORRHOEA (Menstrual cramps), ABDOMINAL DISTENSION (Bloating in stomach area) and INTERMENSTRUAL BLEEDING (Spotting). On 07-Jun-2021, the patient experienced PAIN (Pain). On 08-Jun-2021, the patient experienced FEELING ABNORMAL (Brain fog). 08-Jun-2021, the patient experienced NIGHT SWEATS (Night sweats). On an unknown date, the patient experienced CHRONIC FATIGUE SYNDROME (Chronic Fatigue Syndrome). The patient was treated with ESTROGENS CONJUGATED, MEDROXYPROGESTERONE ACETATE (PREMPRO) on 21-May-2021 for Night sweats and Sleeplessness, at an unspecified dose and frequency. On 28-May-2021, INSOMNIA (Sleeplessness) had resolved. At the time of the report, PAIN (Pain), FEELING ABNORMAL (Brain fog), DYSMENORRHOEA (Menstrual cramps), ABDOMINAL DISTENSION (Bloating in stomach area), INTERMENSTRUAL BLEEDING (Spotting) and FATIGUE (Fatigue) had not resolved and NIGHT SWEATS (Night sweats) and CHRONIC FATIGUE SYNDROME (Chronic Fatigue Syndrome) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-May-2021, Blood pressure measurement (115-75): 124/84 (Inconclusive) Unknown. On 28-May-2021, Weight increased: increased (High) Increased. On 07-Jun-2021, Blood pressure measurement (115-75): 134/84 (High) Unknown.         No Concomitant Medications were  provided.  On 20-may-2021, patient experienced elevation in blood pressure which was extremely high on 7-jun-2021 with 134/84. On 05-jun-2021, patient experienced menstrual cramps and extreme fatigue with no sleep of about 8 hours. Patient stated that she is now menstruating due to Medications.   This case was linked to US-MODERNATX, INC.-MOD-2021-116386 (E2B Linked Report). This case was linked to MOD-2021-222815, MOD-2021-222815 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-116386:Husband's case
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient was 17 years old at time of vaccination; This spontaneous case was reported by an other caregiver and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient was 17 years old at time of vaccination) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     The patient's past medical history included Asthma (chronic).    On 09-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jun-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient was 17 years old at time of vaccination). On 09-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient was 17 years old at time of vaccination) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant information use was not reported.  Treatment information was not provided.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pain in extremity, Pyrexia, Tenderness, Vaccination site swelling
Clinical narrative: new onset of redness at the injection site; swelling of the injection arm; fever; arm soreness which was quite bad; injection arm is tender; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness which was quite bad), TENDERNESS (injection arm is tender), ERYTHEMA (new onset of redness at the injection site), VACCINATION SITE SWELLING (swelling of the injection arm) and PYREXIA (fever) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049C21A) for COVID-19 vaccination.     Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL HCTZ) for Hypertension.   On 05-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jun-2021, the patient experienced PAIN IN EXTREMITY (arm soreness which was quite bad), TENDERNESS (injection arm is tender), VACCINATION SITE SWELLING (swelling of the injection arm) and PYREXIA (fever). On 08-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ERYTHEMA (new onset of redness at the injection site). The patient was treated with IBUPROFEN at a dose of 1 UNK and IBUPROFEN (ADVIL [IBUPROFEN]) at a dose of 1 UNK. At the time of the report, PAIN IN EXTREMITY (arm soreness which was quite bad), TENDERNESS (injection arm is tender), ERYTHEMA (new onset of redness at the injection site), VACCINATION SITE SWELLING (swelling of the injection arm) and PYREXIA (fever) outcome was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Influenza like illness, Pruritus, Rash
Clinical narrative: itchy on my outer thighs, buttocks and the trunk of my body; sore extensive rash on my outer thighs, buttocks and the trunk of my body; flu like symptoms; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), PRURITUS (itchy on my outer thighs, buttocks and the trunk of my body) and RASH (sore extensive rash on my outer thighs, buttocks and the trunk of my body) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Jun-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms). On 09-Jun-2021, the patient experienced PRURITUS (itchy on my outer thighs, buttocks and the trunk of my body) and RASH (sore extensive rash on my outer thighs, buttocks and the trunk of my body). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), PRURITUS (itchy on my outer thighs, buttocks and the trunk of my body) and RASH (sore extensive rash on my outer thighs, buttocks and the trunk of my body) outcome was unknown.            No concomitants medication were provided. No treatment medication were provided. No lab data has been provided by the reporter.